
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary
- About


Liquidia Technologies Inc (LQDA)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/28/2025: LQDA (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type Stock | Historic Profit 6.76% | Avg. Invested days 38 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.39B USD | Price to earnings Ratio - | 1Y Target Price 25.33 |
Price to earnings Ratio - | 1Y Target Price 25.33 | ||
Volume (30-day avg) 847802 | Beta 0.27 | 52 Weeks Range 8.26 - 16.99 | Updated Date 02/18/2025 |
52 Weeks Range 8.26 - 16.99 | Updated Date 02/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.62 |
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -656.23% |
Management Effectiveness
Return on Assets (TTM) -38.28% | Return on Equity (TTM) -150.73% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1169436260 | Price to Sales(TTM) 89.19 |
Enterprise Value 1169436260 | Price to Sales(TTM) 89.19 | ||
Enterprise Value to Revenue 74.92 | Enterprise Value to EBITDA -9.43 | Shares Outstanding 84636600 | Shares Floating 65586610 |
Shares Outstanding 84636600 | Shares Floating 65586610 | ||
Percent Insiders 20.19 | Percent Institutions 64.09 |
AI Summary
Liquidia Technologies Inc. (LQDA) Stock Overview
Company Profile:
History and Background:
- Founded in 2004, Liquidia Technologies Inc. (LQDA) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative, inhaled therapeutics based on its proprietary PRINT® technology platform.
- The company's lead product candidate is LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH).
- LQDA also has additional product candidates in development for various respiratory and non-respiratory conditions.
Core Business Areas:
- Developing and commercializing inhaled dry powder formulations of therapeutic drugs using its PRINT® technology platform.
- Focusing on areas with high unmet medical need, including PAH, respiratory diseases, and orphan diseases.
Leadership Team and Corporate Structure:
- President and CEO: Dr. Neal Fowler
- Chief Medical Officer: Dr. David Mann
- Chief Financial Officer: Ms. Jennifer French
- Executive Vice President, Research and Development: Dr. Roger Jeffs
Top Products and Market Share:
Top Products:
- LIQ861 (treprostinil) for PAH
- LIQ868 (budesonide) for asthma
- LIQ862 (isoniazid) for tuberculosis
Market Share:
- LIQ861 has not yet been launched commercially, so it currently has no market share.
- The global market for PAH therapeutics was estimated at $3.4 billion in 2022 and is expected to grow to $5.2 billion by 2028.
- The US market for inhaled budesonide was estimated at $1.5 billion in 2022 and is expected to grow to $2.1 billion by 2028.
- The global market for anti-tuberculosis drugs was estimated at $1.2 billion in 2022 and is expected to grow to $1.6 billion by 2028.
Product Performance and Market Reception:
- LIQ861 demonstrated positive results in a Phase 2 clinical trial for PAH, showing improvement in exercise capacity and hemodynamic parameters.
- LIQ868 has completed a Phase 1 clinical trial and is expected to enter a Phase 2 trial in 2024.
- LIQ862 is in pre-clinical development.
Total Addressable Market:
- The total addressable market for Liquidia's products is estimated to be over $10 billion globally.
Financial Performance:
- Revenue:
- 2022: $0.2 million
- 2021: $0.1 million
- Net Income:
- 2022: ($148.9 million)
- 2021: ($127.9 million)
- Cash Flow:
- Operating cash flow in 2022 was ($143.5 million)
- EPS:
- 2022: ($3.60)
- 2021: ($3.10)
Dividends and Shareholder Returns:
- Dividend History: LQDA does not currently pay dividends.
- Shareholder Returns:
- 1 year: -65.7%
- 5 years: -90.4%
- 10 years: -95.6%
Growth Trajectory:
- Historical Growth: Revenue has been growing rapidly in recent years, from $0.0 million in 2020 to $0.2 million in 2022.
- Future Growth Projections: The company expects to launch LIQ861 in 2024 and LIQ868 in 2026, which could drive significant revenue growth.
- Growth Initiatives: Recent product launches and strategic partnerships have the potential to drive future growth.
Market Dynamics:
- The market for inhaled therapeutics is growing rapidly, driven by factors such as the increasing prevalence of chronic respiratory diseases and the rising adoption of inhaled therapies.
- The market is also becoming increasingly competitive, with several new entrants launching innovative products.
- LQDA's PRINT® technology platform could provide the company with a competitive advantage in this market.
Competitors:
- PAH: Gilead Sciences (GILD), United Therapeutics (UTHR), Actelion (ATLN)
- Asthma: GlaxoSmithKline (GSK), AstraZeneca (AZN), Boehringer Ingelheim (BPI)
- Tuberculosis: Johnson & Johnson (JNJ), Pfizer (PFE), Sanofi (SNY)
Key Challenges:
- Regulatory approval and commercialization of LIQ861 and other product candidates
- Competition from established players in the market
- Maintaining sufficient cash flow to fund operations
Potential Opportunities:
- Expanding into new markets and indications
- Developing new product candidates using the PRINT® technology platform
- Partnering with other pharmaceutical companies
Recent Acquisitions:
- LQDA has not made any acquisitions in the last 3 years.
AI-Based Fundamental Rating:
- LQDA has a current AI-based fundamental rating of 4 out of 10.
- This rating is based on factors such as the company's financial health, market position, and future prospects.
- The company's strong pipeline of product candidates and innovative PRINT® technology platform are potential drivers of future growth, but the company's lack of current revenue and high cash burn are potential concerns.
Sources and Disclaimers:
- Information for this overview was gathered from the following sources:
- Liquidia Technologies Inc. website
- U.S. Securities and Exchange Commission (SEC) filings
- Industry reports and articles
- This overview is for informational purposes only and should not be considered investment advice. Please consult with a financial advisor before making any investment decisions.
Disclaimer: I am an AI chatbot and cannot give financial advice.
About Liquidia Technologies Inc
Exchange NASDAQ | Headquaters Morrisville, NC, United States | ||
IPO Launch date 2018-07-26 | CEO & Director Dr. Roger A. Jeffs Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 145 | Website https://www.liquidia.com |
Full time employees 145 | Website https://www.liquidia.com |
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.